Published in Antimicrob Agents Chemother on July 11, 2011
The Acinetobacter baumannii Oxymoron: Commensal Hospital Dweller Turned Pan-Drug-Resistant Menace. Front Microbiol (2012) 2.45
CTX-M Enzymes: Origin and Diffusion. Front Microbiol (2012) 2.37
Antimicrobial treatment and containment measures for an extremely drug-resistant Klebsiella pneumoniae ST101 isolate carrying pKPN101-IT, a novel fully sequenced bla(KPC-2) plasmid. J Clin Microbiol (2012) 1.19
Prevalence and molecular epidemiology of acquired AmpC β-lactamases and carbapenemases in Enterobacteriaceae isolates from 35 hospitals in Spain. Eur J Clin Microbiol Infect Dis (2012) 1.14
Derepressed transfer properties leading to the efficient spread of the plasmid encoding carbapenemase OXA-48. Antimicrob Agents Chemother (2013) 1.14
Spread of NDM-1-producing Enterobacteriaceae in a neonatal intensive care unit in Istanbul, Turkey. Antimicrob Agents Chemother (2014) 1.09
Global Dissemination of Carbapenemase-Producing Klebsiella pneumoniae: Epidemiology, Genetic Context, Treatment Options, and Detection Methods. Front Microbiol (2016) 1.07
Whole genome sequence analysis of the first Australian OXA-48-producing outbreak-associated Klebsiella pneumoniae isolates: the resistome and in vivo evolution. PLoS One (2013) 1.04
Molecular characterization of blaNDM-5 carried on an IncFII plasmid in an Escherichia coli isolate from a nontraveler patient in Spain. Antimicrob Agents Chemother (2014) 1.01
Fecal carriage of carbapenemase-producing Enterobacteriaceae: a hidden reservoir in hospitalized and nonhospitalized patients. J Clin Microbiol (2012) 0.99
Comparative population analysis of Klebsiella pneumoniae strains with extended-spectrum β-lactamases colonizing patients in rehabilitation centers in four countries. Antimicrob Agents Chemother (2013) 0.97
Prospective multicenter study of carbapenemase-producing Enterobacteriaceae from 83 hospitals in Spain reveals high in vitro susceptibility to colistin and meropenem. Antimicrob Agents Chemother (2015) 0.95
French regional surveillance program of carbapenemase-producing Gram-negative bacilli: results from a 2-year period. Eur J Clin Microbiol Infect Dis (2014) 0.88
Dissemination of the Klebsiella pneumoniae carbapenemase in the health care settings: tracking the trails of an elusive offender. MBio (2011) 0.85
Detection of β -Lactamases and Outer Membrane Porins among Klebsiella pneumoniae Strains Isolated in Iran. Scientifica (Cairo) (2014) 0.82
Carbapenem-resistant and carbapenem-susceptible isogenic isolates of Klebsiella pneumoniae ST101 causing infection in a tertiary hospital. BMC Microbiol (2015) 0.81
Carbapenem-hydrolyzing class D β-lactamase OXA-48 in Klebsiella pneumoniae isolates from Tunisia. Eur J Clin Microbiol Infect Dis (2011) 0.79
Carbapenemase-Producing Klebsiella pneumoniae in Romania: A Six-Month Survey. PLoS One (2015) 0.78
Rapid Detection of OXA-48-Producing Enterobacteriaceae by Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry. J Clin Microbiol (2015) 0.78
LN-1-255, a penicillanic acid sulfone able to inhibit the class D carbapenemase OXA-48. J Antimicrob Chemother (2016) 0.76
First description of OXA-48-producing Escherichia coli and the pandemic clone ST131 from patients hospitalised at a military hospital in Algeria. Eur J Clin Microbiol Infect Dis (2014) 0.76
Phylogeny, resistome and mobile genetic elements of emergent OXA-48 and OXA-245 Klebsiella pneumoniae clones circulating in Spain. J Antimicrob Chemother (2016) 0.76
Outbreak of OXA-48-Producing Klebsiella pneumoniae Involving a Sequence Type 101 Clone in Batna University Hospital, Algeria. Antimicrob Agents Chemother (2016) 0.75
Laboratory Detection and Clinical Implication of Oxacillinase-48 like Carbapenemase: The Hidden Threat. J Glob Infect Dis (2016) 0.75
Rapid procedure for detection and isolation of large and small plasmids. J Bacteriol (1981) 45.21
Detection of plasmid-mediated AmpC beta-lactamase genes in clinical isolates by using multiplex PCR. J Clin Microbiol (2002) 12.53
Multilocus sequence typing of Klebsiella pneumoniae nosocomial isolates. J Clin Microbiol (2005) 11.50
Characterization of VIM-2, a carbapenem-hydrolyzing metallo-beta-lactamase and its plasmid- and integron-borne gene from a Pseudomonas aeruginosa clinical isolate in France. Antimicrob Agents Chemother (2000) 10.05
Emergence of carbapenem-resistant Klebsiella species possessing the class A carbapenem-hydrolyzing KPC-2 and inhibitor-resistant TEM-30 beta-lactamases in New York City. Clin Infect Dis (2004) 9.21
Emergence of oxacillinase-mediated resistance to imipenem in Klebsiella pneumoniae. Antimicrob Agents Chemother (2004) 7.96
Imipenem resistance in Klebsiella pneumoniae is associated with the combination of ACT-1, a plasmid-mediated AmpC beta-lactamase, and the foss of an outer membrane protein. Antimicrob Agents Chemother (1997) 7.07
Complex clonal and plasmid epidemiology in the first outbreak of Enterobacteriaceae infection involving VIM-1 metallo-beta-lactamase in Spain: toward endemicity? Clin Infect Dis (2007) 4.51
Acquired carbapenemases in Gram-negative bacterial pathogens: detection and surveillance issues. Clin Microbiol Infect (2010) 4.07
Spread of OXA-48-encoding plasmid in Turkey and beyond. Antimicrob Agents Chemother (2010) 3.15
Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey. Antimicrob Agents Chemother (2008) 2.97
Outbreak of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in France. Antimicrob Agents Chemother (2011) 2.38
Functional characterization of IS1999, an IS4 family element involved in mobilization and expression of beta-lactam resistance genes. J Bacteriol (2006) 2.09
Genetic factors associated with elevated carbapenem resistance in KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother (2010) 1.94
Plasmid-encoded carbapenem-hydrolyzing beta-lactamase OXA-48 in an imipenem-susceptible Klebsiella pneumoniae strain from Belgium. Antimicrob Agents Chemother (2008) 1.93
Class D OXA-48 carbapenemase in multidrug-resistant enterobacteria, Senegal. Emerg Infect Dis (2011) 1.74
Characterization of a large outbreak by CTX-M-1-producing Klebsiella pneumoniae and mechanisms leading to in vivo carbapenem resistance development. J Clin Microbiol (2006) 1.73
Role of Klebsiella pneumoniae OmpK35 porin in antimicrobial resistance. Antimicrob Agents Chemother (2003) 1.54
First detection of oxacillinase-mediated resistance to carbapenems in Klebsiella pneumoniae from Morocco. Ann Trop Med Parasitol (2010) 1.48
Plasmid-encoded OXA-48 carbapenemase in Escherichia coli from Israel. J Antimicrob Chemother (2010) 1.34
Emergence of bla KPC-3-Tn4401a associated with a pKPN3/4-like plasmid within ST384 and ST388 Klebsiella pneumoniae clones in Spain. J Antimicrob Chemother (2010) 1.33
Plasmid-mediated carbapenem-hydrolysing OXA-48 beta-lactamase in Klebsiella pneumoniae from Tunisia. Int J Antimicrob Agents (2010) 1.27
Oxacillinase-mediated resistance to carbapenems in Klebsiella pneumoniae from Lebanon. Clin Microbiol Infect (2008) 1.23
Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis (2008) 8.58
Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology (2002) 2.93
The Acinetobacter baumannii Oxymoron: Commensal Hospital Dweller Turned Pan-Drug-Resistant Menace. Front Microbiol (2012) 2.45
Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis (2003) 2.13
Risk factors for community-onset urinary tract infections due to Escherichia coli harbouring extended-spectrum beta-lactamases. J Antimicrob Chemother (2006) 2.13
Comparison of antimicrobial cycling and mixing strategies in two medical intensive care units. Crit Care Med (2006) 1.89
[Etiology and antimicrobial susceptibility among uropathogens causing community-acquired lower urinary tract infections: a nationwide surveillance study]. Enferm Infecc Microbiol Clin (2005) 1.77
Brief communication: treatment of Enterococcus faecalis endocarditis with ampicillin plus ceftriaxone. Ann Intern Med (2007) 1.69
Mechanisms of resistance in multiple-antibiotic-resistant Escherichia coli strains of human, animal, and food origins. Antimicrob Agents Chemother (2004) 1.66
Changing epidemiology of central venous catheter-related bloodstream infections: increasing prevalence of Gram-negative pathogens. J Antimicrob Chemother (2011) 1.60
Extended virulence genotypes and phylogenetic background of Escherichia coli isolates from patients with cystitis, pyelonephritis, or prostatitis. J Infect Dis (2004) 1.58
Hospitalized community-acquired pneumonia due to Streptococcus pneumoniae: Has resistance to antibiotics decreased? Chest (2006) 1.58
Etiology of diarrhea in children younger than 5 years of age admitted in a rural hospital of southern Mozambique. Am J Trop Med Hyg (2007) 1.57
Efficacy of linezolid compared to vancomycin in an experimental model of pneumonia induced by methicillin-resistant Staphylococcus aureus in ventilated pigs. Crit Care Med (2012) 1.54
Salmonella enterica serovar Typhimurium skills to succeed in the host: virulence and regulation. Clin Microbiol Rev (2013) 1.52
First description of an Escherichia coli strain producing NDM-1 carbapenemase in Spain. Antimicrob Agents Chemother (2011) 1.48
Evaluation of a new, rapid, simple test for the detection of influenza virus. BMC Infect Dis (2015) 1.47
The Effect of Macrolide Resistance on the Presentation and Outcome of Patients Hospitalized for Streptococcus pneumoniae Pneumonia. Am J Respir Crit Care Med (2015) 1.46
Clinical features and epidemiology of Acinetobacter baumannii colonization and infection in Spanish hospitals. Infect Control Hosp Epidemiol (2004) 1.46
[Clonal diversity and antimicrobial susceptibility of Acinetobacter baumannii isolated in Spain. A nationwide multicenter study: GEIH-Ab project (2000)]. Enferm Infecc Microbiol Clin (2004) 1.41
[Comparison of 3 methods for determining sensitivity to imipenem and meropenem in Acinetobacter baumannii with a carbapenem-heteroresistant phenotype]. Enferm Infecc Microbiol Clin (2008) 1.39
Emergence of coagulase-negative staphylococci as a cause of native valve endocarditis. Clin Infect Dis (2008) 1.37
Quinolone-resistant uropathogenic Escherichia coli strains from phylogenetic group B2 have fewer virulence factors than their susceptible counterparts. J Clin Microbiol (2005) 1.36
Blood cultures for women with uncomplicated acute pyelonephritis: are they necessary? Clin Infect Dis (2003) 1.32
Epidemiology, species distribution and in vitro antifungal susceptibility of fungaemia in a Spanish multicentre prospective survey. J Antimicrob Chemother (2012) 1.31
Etiology of diarrhea in children less than five years of age in Ifakara, Tanzania. Am J Trop Med Hyg (2004) 1.31
A role for human Sp alpha as a pattern recognition receptor. J Biol Chem (2005) 1.31
In vitro antimicrobial susceptibility of clinical isolates of Aeromonas caviae, Aeromonas hydrophila and Aeromonas veronii biotype sobria. J Antimicrob Chemother (2002) 1.29
Foodborne nosocomial outbreak of SHV1 and CTX-M-15-producing Klebsiella pneumoniae: epidemiology and control. Clin Infect Dis (2011) 1.26
Differences in virulence factors among clinical isolates of Escherichia coli causing cystitis and pyelonephritis in women and prostatitis in men. J Clin Microbiol (2002) 1.23
Efficacy of telavancin in the treatment of experimental endocarditis due to glycopeptide-intermediate Staphylococcus aureus. Antimicrob Agents Chemother (2007) 1.21
Influence of multidrug resistance and appropriate empirical therapy on the 30-day mortality rate of Pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother (2012) 1.20
A double mutation in the gyrA gene is necessary to produce high levels of resistance to moxifloxacin in Campylobacter spp. clinical isolates. Int J Antimicrob Agents (2005) 1.20
Relationship between mutations in the gyrA gene and quinolone resistance in clinical isolates of Corynebacterium striatum and Corynebacterium amycolatum. Antimicrob Agents Chemother (2005) 1.19
Prospective multicenter study of the epidemiology, molecular identification, and antifungal susceptibility of Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis isolated from patients with candidemia. Antimicrob Agents Chemother (2011) 1.17
Mechanism of action of and resistance to quinolones. Microb Biotechnol (2008) 1.16
Development of imipenem resistance in an Aeromonas veronii biovar sobria clinical isolate recovered from a patient with cholangitis. J Med Microbiol (2009) 1.16
Treatment of multiresistant Acinetobacter baumannii infections. Curr Opin Investig Drugs (2009) 1.13
Phylogenetic analysis of viridans group streptococci causing endocarditis. J Clin Microbiol (2008) 1.10
Characterization of the carbapenem-hydrolyzing oxacillinase oxa-58 in an Acinetobacter genospecies 3 clinical isolate. Antimicrob Agents Chemother (2008) 1.10
Clinical impact and molecular basis of antimicrobial resistance in non-baumannii Acinetobacter. Future Microbiol (2011) 1.09
In vitro activity of doripenem against Acinetobacter baumannii clinical isolates. Int J Antimicrob Agents (2008) 1.08
High prevalence of nalidixic acid resistant, ciprofloxacin susceptible phenotype among clinical isolates of Escherichia coli and other Enterobacteriaceae. Diagn Microbiol Infect Dis (2002) 1.08
High-dose daptomycin plus fosfomycin is safe and effective in treating methicillin-susceptible and methicillin-resistant Staphylococcus aureus endocarditis. Antimicrob Agents Chemother (2012) 1.08
Mechanism of resistance to several antimicrobial agents in Salmonella Clinical isolates causing traveler's diarrhea. Antimicrob Agents Chemother (2004) 1.07
Neglecting Enterococci May Lead to a Misinterpretation of the Consequences of Last Changes in Endocarditis Prophylaxis American Heart Association Guidelines. J Am Coll Cardiol (2015) 1.07
Effect of the efflux pump inhibitor Phe-Arg-beta-naphthylamide on the MIC values of the quinolones, tetracycline and chloramphenicol, in Escherichia coli isolates of different origin. J Antimicrob Chemother (2004) 1.06
Relationship of phylogenetic background, biofilm production, and time to detection of growth in blood culture vials with clinical variables and prognosis associated with Escherichia coli bacteremia. J Clin Microbiol (2006) 1.06
Group A streptococcal infections in injection drug users in Barcelona, Spain: epidemiologic, clinical, and microbiologic analysis of 3 clusters of cases from 2000 to 2003. Medicine (Baltimore) (2006) 1.05
Ribonucleotide reductases of Salmonella typhimurium: transcriptional regulation and differential role in pathogenesis. PLoS One (2010) 1.03
Growth of Acinetobacter baumannii in pellicle enhanced the expression of potential virulence factors. PLoS One (2011) 1.03
Biofilm formation at the solid-liquid and air-liquid interfaces by Acinetobacter species. BMC Res Notes (2011) 1.03
Activity of clinafloxacin, compared with six other quinolones, against Acinetobacter baumannii clinical isolates. J Antimicrob Chemother (2002) 1.03
Molecular epidemiology and evolution of resistance to quinolones in Escherichia coli after prolonged administration of ciprofloxacin in patients with prostatitis. J Antimicrob Chemother (2002) 1.02
Evolution of antimicrobial resistance in enteroaggregative Escherichia coli and enterotoxigenic Escherichia coli causing traveller's diarrhoea. J Antimicrob Chemother (2009) 1.02
In vitro activity of clinafloxacin in comparison with other quinolones against Stenotrophomonas maltophilia clinical isolates in the presence and absence of reserpine. Diagn Microbiol Infect Dis (2002) 1.02
Potential virulence and antimicrobial susceptibility of Aeromonas popoffii recovered from freshwater and seawater. FEMS Immunol Med Microbiol (2002) 1.02
Prevalence of pathogenicity island IICFT073 genes among extraintestinal clinical isolates of Escherichia coli. J Clin Microbiol (2005) 1.00
Serotypes and clones causing invasive pneumococcal disease before the use of new conjugate vaccines in Catalonia, Spain. J Infect (2011) 1.00
Quinolone resistance in the food chain. Int J Antimicrob Agents (2008) 1.00
First identification and characterization of an AdeABC-like efflux pump in Acinetobacter genomospecies 13TU. Antimicrob Agents Chemother (2011) 0.99
Partial characterization of a transposon containing the tet(A) determinant in a clinical isolate of Acinetobacter baumannii. J Antimicrob Chemother (2003) 0.99
Molecular and functional characterization of mouse S5D-SRCRB: a new group B member of the scavenger receptor cysteine-rich superfamily. J Immunol (2011) 0.98
Effect of an efflux pump inhibitor on the MIC of nalidixic acid for Acinetobacter baumannii and Stenotrophomonas maltophilia clinical isolates. J Antimicrob Chemother (2002) 0.98
Characterization of the carbapenem-hydrolyzing oxacillinase OXA-58 in an Acinetobacter phenon 6/ct13TU clinical isolate. Diagn Microbiol Infect Dis (2008) 0.98
Efficacy and safety of outpatient parenteral antibiotic therapy for infective endocarditis: a ten-year prospective study. Enferm Infecc Microbiol Clin (2011) 0.98
Pseudomonas aeruginosa isolates in severe chronic obstructive pulmonary disease: characterization and risk factors. BMC Pulm Med (2014) 0.97
Genetic variability among ampC genes from acinetobacter genomic species 3. Antimicrob Agents Chemother (2008) 0.97
Proteomic analysis of a fraction enriched in cell envelope proteins of Acinetobacter baumannii. Proteomics (2006) 0.97
Expression of interleukin-8 receptors (CXCR1 and CXCR2) in premenopausal women with recurrent urinary tract infections. Clin Diagn Lab Immunol (2005) 0.96
Failure of Lactobacillus spp. to prevent bacterial translocation in a rat model of experimental cirrhosis. J Hepatol (2002) 0.96
Molecular characterization of the gene encoding a new AmpC beta-lactamase in a clinical strain of acinetobacter genomic species 3. Antimicrob Agents Chemother (2004) 0.96
Characterization of an integron carrying a new class D beta-lactamase (OXA-37) in Acinetobacter baumannii. Microb Drug Resist (2002) 0.96
Review on bacterial stress topics. Ann N Y Acad Sci (2007) 0.96
Bacterial and fungal bloodstream isolates from 796 hematopoietic stem cell transplant recipients between 1991 and 2000. Ann Hematol (2004) 0.95
Plasmid-mediated QnrS2 determinant from a clinical Aeromonas veronii isolate. Antimicrob Agents Chemother (2008) 0.94
Mutations in gyrA and parC QRDRs are not relevant for quinolone resistance in epidemiological unrelated Stenotrophomonas maltophilia clinical isolates. Microb Drug Resist (2002) 0.94
First identification of OXA-72 carbapenemase from Acinetobacter pittii in Colombia. Antimicrob Agents Chemother (2012) 0.94
Prevalence of IS(Aba1) in epidemiologically unrelated Acinetobacter baumannii clinical isolates. FEMS Microbiol Lett (2007) 0.93
Globally expanding carbapenemase finally appears in Spain: nosocomial outbreak of acinetobacter baumannii producing plasmid-encoded OXA-23 in Barcelona, Spain. Antimicrob Agents Chemother (2013) 0.93
Genotypic diversity of coagulase-negative staphylococci causing endocarditis: a global perspective. J Clin Microbiol (2008) 0.93
Detection of dihydrofolate reductase genes by PCR and RFLP. Diagn Microbiol Infect Dis (2003) 0.93
Constitutive SoxS expression in a fluoroquinolone-resistant strain with a truncated SoxR protein and identification of a new member of the marA-soxS-rob regulon, mdtG. Antimicrob Agents Chemother (2009) 0.92
Epidemiology of Clostridium difficile infection and risk factors for unfavorable clinical outcomes: results of a hospital-based study in Barcelona, Spain. J Clin Microbiol (2013) 0.92
In vitro fluoroquinolone-resistant mutants of Salmonella enterica serotype Enteritidis: analysis of mechanisms involved in resistance. Int J Antimicrob Agents (2003) 0.91